Despite the suppression of viral replication induced by the highly active anti-retroviral therapy (HAART), an increased immune activation and inflammatory state persists in HIVinfected patients, contributing to lower treatment response and immune reconstitution, and development of non-AIDS conditions. The chronic activation and inflammation affect the functionality and differentiation of CD8 + T-cells, particularly reducing their cytotoxic capacity, which is critical in the control of HIV replication. Although previous studies have shown that HAART induce a partial immune reconstitution, its effect on CD8
as well as its relationship with the inflammatory state, is yet to be defined. Here, we characterized the functional profile of polyclonal and HIV-specific CD8 + T cells, based on the expression of cell activation and differentiation markers, in individuals chronically infected with HIV, under HAART. Compared with seronegative controls, CD8 + T-cells from patients on HAART exhibited a low degranulation capacity (surface expression of CD107a), with consequent low secreted levels and high intracellular expression of granzyme B and perforin. This degranulation defect was particularly observed in those cells expressing the activation marker HLA-DR, which were further characterized as effector memory cells with high expression of CD57. The expression of CD107a, but not of granzyme B and perforin, in CD8 + T-cells from HIV-infected patients on HAART reached levels similar to those in seronegative controls when the treatment duration was higher than 25 months. In addition, the expression of CD107a was negatively correlated with the expression of exhaustion markers on CD8 + T-cells and the plasma inflammatory molecule sCD14. Thus, despite HAARTinduced viral suppression, CD8 + T-cells from HIV-infected patients have an alteration in their cytotoxic program. This defect is associated with the cellular activation, differentiation and exhaustion state, as well as with the inflammation levels, and can be partially recovered with a long and continuous treatment.
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Introduction
It is well stablished that CD8 + T-cells are critical in the control of HIV infection [1] . Circulating CD8 + T-cells are characterized by a high cytotoxic capacity, which depends on both the lytic granule contents (particularly granzymes and perforin), and on the degranulation capacity, widely evaluated by the expression of CD107a [2] [3] . Interestingly, the cytotoxic capacity of circulating CD8 + T-cells is modulated according to their differentiation state: i) naïve CD8 + T-cells have a low granule content, and a reduced degranulation and cytotoxic capacity; ii) effector and terminally differentiated cells exhibit high cytotoxic capacity; and iii) central memory cells have an intermediate cytotoxic function [4] [5] [6] . Importantly, the cytotoxic function of circulating HIV-specific CD8 + T-cells has been associated with the control of viral replication and a delayed progression, highlighting the importance of this effector function [7] [8] [9] . Since its introduction, the highly active anti-retroviral therapy (HAART) has been effective in preventing deaths related with the acquired immune deficiency syndrome (AIDS) in HIVinfected patients. Nonetheless, partial immune restoration has been observed despite HAARTinduced viral suppression [10, 11] . Indeed, one of the major pitfalls of anti-retroviral therapy is the persistent immune activation and inflammation, caused by residual viral replication, ongoing co-infections or microbial translocation across a disturbed gastrointestinal mucosa. These defects are associated with the development of non-AIDS conditions [12] , such as cardiovascular disease or stroke, which reach up to the 42% of deaths among HIV-infected patients [13] . In addition, an important proportion of deaths in HIV-infected patients on HAART results from a poor immune response against new infectious challenges [13, 14] . CD8 + T-cells are affected by the increased activation and inflammatory state in HIVinfected patients. These alterations include: (i) persistently increased absolute counts [15] ; (ii) increase in the pool of total memory cells with an skewed differentiation [16, 17] ; (iii) high expression of the activation markers HLA-DR and CD38, and the exhaustion marker Programmed Death (PD)-1 [18, 19] ; and (iv) low cytotoxic ability [20] . Some of these defects, such as the persistent increase in their absolute counts, activation state and maturation status, are partially reconstituted by HAART [21] [22] [23] , and, the lack of restoration, are associated with the development of therapeutic failure or non-AIDS conditions [24, 25] . Nevertheless, the effect of prolonged HAART-induced viral suppression on the normalization of CD8 + T-cells function, particularly their cytotoxic potential, as well as the relation with the activation/differentiation profile and inflammatory state in these individuals, is yet to be defined. In this study we aimed to evaluate the cytotoxic function and activation/differentiation profile of circulating CD8 + T-cells in a cohort of HIV-infected patients on suppressive HAART, as well as the relation with the inflammatory state and treatment duration. We hypothesized that despite HAART-induced viral suppression, a defect in the cytotoxic program was present in CD8 + T-cells from HIV-infected patients, and it was directly associated with a high immune activation and inflammation, their differentiation status, and a short treatment duration.
Materials and methods

Patients and samples
This study was approved by the Institutional Review Board of Universidad de Antioquia (certificates 15-08-634 and 11-08-352). All experiments followed the principles expressed in the Declaration of Helsinki. All the individuals signed the informed consent. Thirty HIV-infected patients who received only one therapeutic HAART scheme for more than one year, with undetectable viral load (<20 HIV RNA copies/mL) and without previous therapeutic failure, were included from April to December, 2017. A control group of 15 seronegative individuals was also evaluated. The characteristics of the patients are described elsewhere [26] . Notably, similar to previous reports [21] [22] [23] , and washed with RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, 100 μg/mL of streptomycin and 2 mM L-glutamine (complete medium) (all from Gibco, Carlsbad, CA). Plasma fraction was used for determining viral load with the clinical diagnostic test RT-PCR Ampliprep-Cobas (Roche, Indianapolis, IN, USA), following the manufacturer's protocol, with a detection limit of 20 copies/mL. In addition, plasma levels of soluble CD14 (sCD14) were measured using the Human sCD14 ELISA Kit (MyBioSource, San Diego, CA), with a limit of detection of 0.18 ng/ mL.
Evaluation of the phenotype of circulating CD8 + T-cells by flow cytometry
One hundred μL of whole blood was incubated for 30 min at room temperature with optimized doses and combinations of the following anti-human antibodies: anti-CD3-PerCP (SK7, BD, San Jose, CA) or anti-CD3-Alexa Fluor 700 (UCHT1, Thermo Fisher, Waltham, MA, USA), anti-CD8-PE (RPA-T8; BD) or anti-CD8-Alexa Fluor 700 (OKT8; Thermo Fisher), anti-CD4-APC-eFluor 780 (RPA-T4, Thermo Fisher), anti-HLA-DR-FITC or APC-eFluor 780 (LN3, Thermo Fisher), anti-CD38-PE Cy7 or PE-eFluor 610 (HIT2, Thermo Fisher), anti-PD-1-PerCP-eFluor 710 (F38-2E2, Thermo Fisher), anti-CCR7-PE (3D12, Thermo Fisher), anti-CD45RO-PE (UCHL1, BD), anti-CD45RA-PE Cy7 (HI100, BD), anti-CD28-PE (L293, BD), anti-CD57-FITC (TB01, Thermo Fisher), anti-CD95-FITC (DX2, BD) and anti-CD152-PE (BNI3, BD Pharmingen). Next, red blood cells were removed with 1X FACS Lysing Solution (BD) during 20 min at room temperature, followed by a washing step with 1 mL of 1X PBS and fixation in 1% paraformaldehyde. The cells were acquired on a LSR Fortessa cytometer (BD), using the FACS Diva software v. 6.0, within one hour of completing the staining; at least 50,000 CD3 + events were acquired. Data were analyzed with the FlowJo Software version 10.4 (Tree Star, Inc, Ashland, OR, USA). Fluorescence minus one control was included to define positive thresholds.
Ex vivo stimulation of CD8 + T-cells
Fresh PBMC, at a density of 2x10 6 cells/mL, were cultured in 96 well V-bottom plates (Costar, Corning, NY). Three different conditions were assessed: 1) cells stimulated only with mouse anti-human CD28 (CD28.2, eBioscience), and CD49d (9F10, eBioscience) functional grade purified antibodies (both at 1 μg/mL), that were used as negative control; 2) cells stimulated with phorbol 12-myristate 13-acetate (PMA), and ionomycin (at 50 and 500 ng/mL, respectively; both from Sigma-Aldrich); 3) cells stimulated with anti-CD28 and anti-CD49d (both at 1 μg/mL) plus a pool of HIV-1 consensus B Gag peptides (at 5 μg/mL) (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH; Cat: 8117, Lot: 140303). All conditions were incubated for the indicated hours at 37˚C in 5% CO 2 , in the presence of 5 μg/mL of brefeldin A, and monensin (both from Thermo Fisher), as well as anti-human CD107a-APC (H4A3, BD). After incubation, the levels of cell death were evaluated by the incorporation of the Fixable Viability Dye eFluor 506 (Thermo Fisher) or propidium iodide (PI), and the expression of Annexin V (TACS Annexin V Kits; Trevigen). Next, PBMC were harvested and washed with 2 mL of 1X PBS. Afterwards, lineage antibody cocktail for cell surface staining was added and incubated for 30 min at 4˚C, light-protected, followed by a wash, cell fixation and permeabilization with Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher). Then, proper doses of the following mouse anti-human antibodies were added and incubated for 30 min at 4˚C, light-protected: anti-granzyme B-FITC (GB11, BD), anti-perforin-PE (D48, Biolegend, San Diego, CA) and anti-Interferon (IFN)-γ-PE Cy7 (4SB3, Thermo Fisher). Finally, the cells were washed twice with 1X permeabilization solution (Thermo Fisher) and acquired on a LSR Fortessa cytometer (BD). At least 25,000 CD3 + CD8 + events were acquired.
Fluorescence minus one control was also included. Of note, we used an anti-perforin antibody clone that detects both preformed and de novo produced perforin after activation [27, 28] . In a fraction of the experiments, cells were cultured in the absence of brefeldin A and monensin, and the supernatants were collected.
Measurement of granzyme B levels in culture supernatant
The Human granzyme B Flex Set kit (BD) was used for the detection of the respective molecule in supernatants of cultured PBMC, following manufacturer´s protocols. Samples were acquired within an hour following the procedure. The detection limit was 4 pg/mL. 
Ex vivo cytotoxicity assay
Results
Establishing the kinetics of CD8 + T-cells activation and degranulation
We first characterized, in seronegative individuals, the dynamics of the surface expression of the activation markers HLA-DR and CD38, the exhaustion marker PD-1, the degranulation marker CD107a, and the intracellular expression of perforin, granzyme B and IFN-γ, from 0 to 24 hours after polyclonal stimulation with PMA-Ionomycin, following the gating strategy shown in S1A Fig. At (Fig 1A) . Finally, there were no changes in the proportion of HLA-DR -CD38 + cells ( Fig 1A) . Altered cytotoxic CD8 + T-cells in HIV Consistent with previous reports [31, 32] , the expression of PD-1 increased after 6 hours of stimulation, with a peak at 12 hours (Fig 1B) , followed by a decrease in their levels after 18 hours of culture (Fig 1B) (Fig 1C) . Of note, in the unstimulated cells control, the frequencies of HLA-DR/CD38/PD-1-expressing cells, as well as those of dead cells, where similar to those seen in stimulated cells at 0 hours, and remained constant at all time points (S1B-S1D Fig) .
When we evaluated the intracellular expression of cytotoxic molecules, at 0 hours of culture, an important proportion of CD8 + T-cells expressed granzyme B and perforin when they were measured independent or simultaneously ( Fig 1D) . Similar to previous reports [2, 28, 35] , there was a rapid up-regulation of both cytotoxic molecules between 2 and 6 hours of stimulation, followed by a decrease after 12 hours (Fig 1D) , consistent with their release after cell degranulation [2, 35] . In addition, the expression of CD107a continuously increased from 2 to 12 hours of culture, with a subsequent decrease ( Fig 1E) . Moreover, an important fraction of CD107a + cells co-expressed perforin or granzyme B, indicative of de novo production of these cytotoxic molecules [28] (Fig 1E) . Finally, the expression of IFN-γ, alone or together with granzyme B and CD107a continuously increased from 2 to 12 hours of culture, followed by a decrease in the proportion of these cells after 12 hours of culture ( Fig 1F) . As expected, there were no changes in the expression of granzyme B and perforin in unstimulated cells (S1E Fig Since the co-expression of granzyme B or perforin and CD107a is indicative of de novo production and granule recruitment of the cytotoxic molecules [28] , these results suggest an alteration in the bulk degranulation ability of CD8 + T-cells in HIV-infected individuals, but not in the de novo production of cytotoxic molecules [28] . Considering that previous reports [2, 35] + perforin + and CD107a + CD8 + T-cells in seronegative and HIV-infected individuals (n = 15 and n = 30, respectively). E. Levels of granzyme B in supernatant of cultured PBMC from seronegative and HIV-infected individuals (n = 7 and n = 15, respectively). The dashed line indicates the assay limit of detection. F. Correlation between the levels of granzyme B in supernatant of cultured PBMC and the frequency of CD107a + CD8 + T-cells in seronegative and HIV-infected individuals after polyclonal stimulation (n = 7 and n = 15, respectively). In A-C and E, the P value of the Mann-Whitney test is shown. In D and F, the rho and P value of the Spearman test are shown.
Low degranulation capacity in CD8 + T-cells from HIV-infected patients despite HAART-induced viral suppression
https://doi.org/10.1371/journal.pone.0210540.g002
Altered cytotoxic CD8 + T-cells in HIV and our kinetic studies (Fig 1D and 1E) . Moreover, we evaluated the levels of granzyme B in culture supernatant from PBMC from seronegative and HIV-infected individuals. Although these levels were higher in cells treated with PMA-ionomycin compared with unstimulated cells in both groups (Fig 2E) , the levels were lower in stimulated cells from HIVinfected patients compared with those from seronegative controls (Fig 2E) . Finally, the correlation between the levels of granzyme B in culture supernatant and the frequency of CD107a + CD8 + T-cells after polyclonal stimulation, was evaluated. A positive correlation was found in seronegative individuals (Fig 2F left panel) , consistent with the release of granzyme B with degranulation, but there was no correlation in HIV-infected patients (Fig 2F right panel) . Thus, CD8 + T-cells from HIV-infected patients have an alteration in their cytotoxic program after polyclonal stimulation, with low degranulation capacity and consequent increased intracellular expression of cytotoxic molecules, but decreased in culture supernatant, which would limit their content in a potential immunological synapse.
HLA-DR + subsets are effector memory cells and exhibit the major cytotoxic potential among CD8 + T-cells; a shift in the differentiation program of CD8 + T-cells from HIV-infected patients
Next, we evaluated the cytotoxic program according to the differential expression of HLA-DR and CD38 in CD8 + T-cells, whose co-expression has been associated with an activated and dysfunctional state of CD8 + T-cells [33] . First, we phenotypically characterized the differentiation state of HLA-DR/CD38-expressing CD8 + T-cells subsets, for exploring an association between the phenotype and the cytotoxic potential. Thus, we evaluated the expression of the differentiation markers CCR7, CD28, CD45RA, CD45RO, CD95, CD57 and Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) in each subset, in resting peripheral blood. As shown in Fig 3A, in seronegative individuals, the expression of HLA-DR was associated with an effector memory phenotype, with high frequency of CD45RO, CD95 and CD57 positive cells, and low frequency of CCR7, CD28 and CTLA-4-positive cells in the HLA-DR + subsets. On the contrary, the expression of CD38 was associated with a resting (naïve) phenotype, characterized by high expression of CD45RA, CCR7 and CD28 [38] . Table 1 . Altogether, these results indicate that, in seronegative individuals, HLA-DR and CD38 characterize late-and early-differentiated CD8 + T-cells, respectively. Although CD38 has been referred as an activation marker [24, 41] , this is true only when is co-expressed with HLA-DR. These results are consistent with the expression of CD38 by T-cells with a naïve phenotype and thymocytes [42, 43] , and the high frequency of HLA-DR -CD38 + T-cells in the early stages of life [44] . Moreover, our results indicate that, in HIV-infected patients, there is a shift to a less differentiated profile in HLA-DR-expressing CD8 + T-cells, and a shift to a more differentiate state in CD38-expressing cells, consistent with the redistribution of memory CD8 + T-cell subsets during this infection [16, 40] . Next, we evaluated the cytotoxic potential of the HLA-DR/CD38-expressing subsets after polyclonal stimulation. As shown in Fig 3B, (Fig 3C) . In contrast, with stimulation, HLA-DR -CD38 + and
HLA-DR -CD38 -cells had a low expression of CD107a (Fig 3B) , whereas had an increase in the co-expression of granzyme B and perforin (Fig 3C) . No significant differences between HLA-DR/CD38-expressing subsets were found for granzyme B/IFN-γ co-expression after stimulation (P�0.1). Furthermore, we evaluated the expression of granzyme B and IFN-γ in CCR7/CD45RA-expressing CD8 + T-cells after PMA-ionomycin stimulation. Similar to previous reports [4, 5] , TEMRA and EM cells from seronegative individuals exhibited the highest expression of granzyme B among CD8 + T-cells, followed by CM and naïve cells (S5 Fig). The production of IFN-γ was also dominated by memory subsets, compared with naïve cells (S5 Fig). Remarkably, naïve cells from HIV-infected patients had a higher expression of granzyme 
CCR7
- Fig 3D) ; these CD57-expressing subsets exhibited a pattern of expression of perforin and CD107a similar to that of total CD8 + T-cells (Fig 3D) . Collectively, our phenotypic and functional characterization of CD8 + T-cell subsets indicate that HLA-DR-expressing cells are an effector memory subset with the highest activation of the cytotoxic program after polyclonal activation among CD8 + T-cells. In HIV-infected patients, despite HAART-induced viral suppression, late-differentiated CD8 + T-cells have a skewed maturation [17] , whereas early-differentiated CD8 + T-cells have a more mature profile [46] . (Fig 4B and 4C ) compared with seronegative donors. Of note, these alterations were particularly observed in HLA-DR + CD38 +/-cells, suggesting that the defect in the cytotoxic program is associated with the expression of HLA-DR. These findings were extended with a t-SNE analysis of merged stimulated CD8 + T-cells from seronegative and HIVinfected individuals (Fig 4D) . Of note, the t-SNE analysis allows to determine the phenotypic relationships from the cell populations evaluated [47] . Compared with seronegative controls, HLA-DR-and CD38-expressing cells were more abundant in HIV-infected patients, and they were characterized by a higher expression of granzyme, perforin and IFN-γ, but a lower expression of CD107 (Fig 4D) , the latter particularly observed in HLA-DR-positive cells. Strikingly, in HIV-infected patients, the frequencies of HLA-DR + CD38 -CD8 + T-cells positively correlated with their respective proportions of granzyme B + perforin + cells (Fig 4E) , but negatively correlated with the frequency of CD107a + cells (Fig 4F) . These associations were not found for the HLA-DR -CD38 + (Fig 4G and 4H) . In summary, HLA-DR-expressing CD8 + T-cells from HIV-infected patients exhibit the main alterations in their cytotoxic program.
HLA-DR + CD8 + T-cells have the major alterations in the cytotoxic program in HIV-infected patients
Most of HIV-specific CD8 + T-cells are effector HLA-DR + cells
To determine if, similar to total CD8 + T-cells, HIV-specific CD8 + T-cells also exhibit an alteration in their cytotoxic potential, we characterized the expression of cytotoxic molecules and (Fig 5A and 5B) . The proportion of granzyme B + perforin + cells did not significantly change after stimulation (S6D Fig), but the supernatant levels of granzyme B were higher in Gag-stimulated cells compared with unstimulated cells (Fig 5C) . Similar to that found in cells from seronegative individuals stimulated with PMA-ionomycin, most of the HIV-specific CD107a + CD8 + T-cells from HIV-infected individuals expressed the HLA-DR + CD38 -phenotype (Fig 5D) , and these cells had the similar peptides. Similar to what we found for total CD8 + T-cells (Fig 2F) , we did not find a correlation between those parameters (Fig 5G) , suggesting that the degranulation capacity, and consequent release of cytotoxic molecules, is also affected in HIV-specific CD8 + T-cells. 
A longer HAART duration is associated with recovery of the cytotoxic program of CD8 + T-cells from HIV-infected patients
To explore the factors associated with the altered cytotoxic program observed in CD8 + T-cells from HIV-infected patients in comparison with seronegative individuals, we performed a Principal Component Analysis (PCA) including the following evaluated parameters: phenotypic and functional characterization of CD8 + T-cells; length of the treatment; CD4:CD8 ratio, and plasma levels of the inflammation marker sCD14. When we evaluated the weight of variables of component 1 (which explains the 32.8% of the variability in the data), as expected, the frequencies of CD107a + CD8 + T-cells, alone or co-expressed with IFN-γ or perforin, were variables with a high weight ( Fig 6A) . Interestingly, the length of treatment, in months, was also a variable of high component weight (Fig 6A) . Indeed, when we divided HIV-infected patients in those with <24 or �25 months of treatment, the PCA yielded two separated clusters of patients, as well as a cluster of seronegative individuals (Fig 6B) . Interestingly, after polyclonal stimulation, HIV-infected patients with �25 months of treatment had a significantly higher frequency of CD107a + CD8 + Tcells than patients with <24 months therapy, reaching levels similar to those in seronegative individuals (Fig 6C) . However, the effect of treatment duration was not evident in the case of granzyme B + perforin + CD8 + T-cells, as HIV-infected, irrespective of their treatment length, had higher frequencies of these cells compared with seronegative individuals (Fig 6D) . Moreover, when we evaluated the effect of treatment duration on the response of HIV-specific CD8 + T-cells, a positive correlation was found between the frequency of CD107a + HIV-specific CD8 + T-cells and the length of the treatment (Fig 6E) . Accordingly, we observed a tendency for a higher in vitro cytotoxic capacity in HIV-specific CD8 + T-cells from patients with �25 months of treatment compared with those from patients with <24 months of therapy (Fig 6F) . Finally, similar results were obtained in HLA-DR/CD38-expressing subsets, although the effect of treatment duration was more evident in the HLA-DR-expressing subsets. Thus, compared with patients with <24 months of treatment, those with �25 months of therapy had higher frequencies of CD107a + HLA-DR + CD38 -and HLA-DR + CD38 + cells (S8A and S8B 
The degranulation ability of CD8 + T-cells from HIV-infected patients is negatively associated with their exhaustion state, and with the systemic inflammation levels
Ultimately, we hypothesized that the exhaustion state of CD8 + T-cells (expression of the inhibitory receptor PD-1), and the systemic inflammation levels (measured by plasma sCD14) in + CD8 + T-cells that are CD107a + after Gag peptides stimulation, the frequency of HLA-DR + CD38 + CD8 + T-cells that are CD107a + after PMA-ionomycin stimulation and the levels of plasma sCD14, in HIV-infected patients (n = 30). In C and D, The P value of the Dunn's post-hoc test is shown. In E, G and H, the rho and P value of the Spearman test are shown.
https://doi.org/10.1371/journal.pone.0210540.g006
Altered cytotoxic CD8 + T-cells in HIV
HIV-infected patients were associated with the altered cytotoxic program of CD8 + T-cells in these individuals. Indeed, similar to previous reports [10, 19] , despite suppressive HAART, HIV-infected patients had higher frequencies of circulating total PD-1 + CD8 + T-cells, and plasma levels of sCD14 than seronegative individuals, without being influenced by treatment duration (S9A and S9B Fig) , evaluated in resting blood (Fig 6G) . This association is supported by the highest expression of PD-1 in HLA-DR + CD38 + CD8 + T-cells [26] . Indeed, compared with patients with <24 months of therapy, the frequency of HLA-DR + CD38 + CD8 + T-cells that are PD-1 + in patients with �25
months of treatment, decreased to levels similar to those in seronegative individuals (S9C Fig), indicating that the major effect of the exhaustion state is on this particular subset, and it can improve with a long continuous treatment. Finally, the frequency of total and HIV-specific HLA-DR + CD38 + CD8 + T-cells that are CD107a
+ , but no other HLA-DR/CD38-expressing or total CD8
+ T-cells, were negatively correlated with the sCD14 levels (Fig 6H) , further supporting a negative effect of the systemic inflammation on these subsets. In summary, the degranulation ability of CD8 + T-cells from HIV-infected patients, particularly those HLA-DR + CD38
+ , is negatively modulated by their exhaustion state and with the systemic inflammation levels.
Discussion
After activation, human circulating CD8 + T-cells rapidly up-regulate perforin, concomitant to degranulation and cytokine production [28] . Subsequently, the degranulation process causes the release of cytotoxic molecules at the immunological synapse-with the simultaneous decrease of intracellular granzyme B and perforin-contributing to the efficient induction of cell death [3] . However, our study evidences that the degranulation capacity of circulating CD8 + T-cells is decreased in HIV-infected patients, resulting in a lower release of cytotoxic granules and an increased intracellular expression of granzyme B and perforin. This functional defect remains despite HAART-induced viral suppression. In addition, similar to previous reports [15, 18, 48, 49] , HIV-infected patients on HAART exhibit persistently increased levels of circulating CD8 + T-cells, high immune exhaustion, chronic immune activation and systemic inflammation. Importantly, in this study, we used T-cell receptor (TCR)-independent (PMA-Ionomycin) and TCR-dependent antigen-specific (Gag peptides) stimulation to assess the cytotoxic potential of CD8 + T-cells from HIV-infected patients on suppressive HAART.
CD8
+ T-cell degranulation requires the activation of cellular Protein Kinases [50] [51] [52] , which are activated by phorbol esters and calcium ionophores [52, 53] . In addition, PMA-ionomycin stimulate de novo synthesis and granule accumulation of cytotoxic molecules in activated CD8 + T-cells [28] , and trigger the lysis of nonantigen-bearing target cells [54, 55] . Altogether, these data support the use of PMA-Ionomycin for the evaluation of the cytotoxic potential of CD8 + T-cells.
Similar to our results, some reports have demonstrated a higher expression of granzyme B and/or perforin in HIV-infected patients on HAART [36, 37, 56, 57] or without treatment [16] , compared with seronegative individuals. However, it has also been observed that perforin expression in HIV-, Epstein-Barr virus (EBV)-and Cytomegalovirus (CMV)-specific CD8 + T-cells is reduced in HIV-infected patients, and this defect is accompanied by a lower expression of granzyme B, and a less differentiated state in HIV-specific cells, but not in cells of other antigen specificities [20] . In addition, in untreated HIV-infected patients, as well as Simian Immune deficiency virus (SIV)-infected macaques, HIV/SIV-specific CD8 + T-cells exhibit a high cytotoxic potential (namely, high expression of perforin and granzyme B) in early infection, but this capacity decreases during chronic infection [58] [59] [60] . In contrast to our results, a previous report showed that CD8 + T-cells from treated HIV-infected patients have a lower expression of perforin and granzyme B after in vitro stimulation with interleukin (IL)-2 or the HIV Envelope protein compared with cells from untreated patients, suggesting that anti-retroviral drugs could have a negative effect in the synthesis of these cytotoxic molecules in CD8 + T-cells [61] . Overall, this would not be the case of total CD8 + T-cells from our cohort of patients under suppressive HAART, as an increased intracellular expression of cytotoxic molecules was evidenced. This could be related to the type of stimulation used in each study, as well as that most of our analyses were based on total, but not antigen-specific, CD8 + T-cells.
In accordance with our results, a low degranulation capacity of antigen-specific CD8 + Tcells in HIV-infected patients, in particular those exhibiting a progressive pattern, in whom a lower expression of CD107a after Gag peptide stimulation was observed, compared with longterm non-progressors patients [7] . HIV infection also impairs the degranulation capacity of Mycobacterium tuberculosis-specific CD8 + T-cells in individuals with untreated HIV and latent tuberculosis coinfection [62] . In addition, in Friend virus infected-mice, a model of chronic retroviral infection, CD8 + T-cells exhibit a degranulation dysfunction [63] . In contrast, other reports have demonstrated that CD8 + T-cells, from chronic untreated HIV-infected patients, maintain their degranulation capacity after superantigen and antigen-specific stimulation [64] , whereas others have demonstrated a comparable degranulation capacity between CD8 + T-cells from different antigen specificities [45] . Importantly, although the surface expression of CD107a associates with the exocytosis of the cytotoxic molecules [2, 35] , it does not directly reflect the CD8 + T-cell cytotoxic capacity, as not all lytic granules contain perforin or granzyme B [4] . Indeed, a previous report showed that perforin can follow a granule-dependent or independent traffic to the immunological synapse, and it can be retained in early endosomal compartments after cell activation [28] . This could be the case for CD8 + T-cells in HIVinfected patients, which have been exposed to chronic activation and might accumulate a high content of perforin. The cytotoxic capacity of human CD8 + T-cells varies according to their transcriptional profile and differentiation state. The Runt-related transcription factor 3 (Runx3), the Tbox transcription factor (T-bet) and Eomesodermin (Eomes), in cooperation, regulate the expression of perforin, granzyme B and IFN-γ [65, 66] . Indeed, the decrease in the cytotoxic potential of HIV and SIV-specific CD8 + T-cells during chronic infection is associated with the expansion of cells expressing low levels of T-bet [58, 59] . Effector and effector memory cells have a high expression of the aforementioned transcription factors and a high cytotoxic potential, followed by central memory and naïve cells [4, 5, 65, 67] . This is consistent with our data showing that most of CD8 + T-cells, responding to polyclonal and antigen-specific stimulation are HLA-DR + cells, which are characterized by an effector memory profile, and, particularly, are composed of a high proportion of CD57 hi cells; in fact, this marker is highly associated with the expression of cytotoxic molecules [5, 45, 68] [20, 70, 71] . This defect does not seem to be restored by HAART [71, 72] . Indeed, our results suggest a defect in the cytotoxic program of HIV-specific CD8 + T-cells despite HAART-induced viral suppression. Thus, the skewed differentiation profile of HIVspecific CD8 + T-cells confer them a lower cytotoxic potential [17, 70] .
In the context of HIV infection, the expression of an efficient cytotoxic program in circulating HIV-specific CD8 + T-cells is critical in the control of viral replication [7, 8] . Of note, most of our results are based on polyclonally-stimulated CD8 + T-cells, and it could be possible that the cytotoxic program of circulating CD8 + T-cells from our cohort of HIV-infected patients in HAART is enough for disease control. Nonetheless, the association with the exhaustion and inflammatory state in HIV-infected patients, supports a cellular defect that could impair the CD8 + T-cells cytotoxic response, particularly in the setting of co-infections or malignancies.
Interestingly, a previous study showed that the frequency of perforin + HIV-specific CD8 + Tcells negatively correlates with the CD4 + T-cells count in treated and untreated patients, and the authors attributed this finding to the chronic activation in these individuals [73] . Indeed, CD8 + T-cells need to be in an activated/effector state for expression of cytotoxic molecules [74] . In addition, the high expression of perforin and/or granzyme B in CD8 + T-cells has been associated with disease severity/activity in patients with herpesvirus reactivation after organ transplantation, and in patients with systemic lupus erythematosus [75, 76] ; in the autoimmune condition, this cytotoxic profile was driven by cell activation [76] . Furthermore, we observed an increase in the degranulation capacity and the in vitro cytotoxicity of total and HIV-specific cells, along treatment time, but not of the expression of cytotoxic molecules, suggesting that reconstitution of these parameters by HAART is incomplete or needs a long treatment duration, as we previously reported [26] . Finally, is important to point that changes induced by HAART in the cytotoxic response of circulating CD8 + T-cells, by evaluating HIV-infected patients before and after treatment initiation, as well as the changes throughout therapy or after treatment failure, required further studies. In addition, it is necessary to clarify it the reported defects in CD8 + T-cells is restricted to HIV-specific cells or includes cells with different specificities. 
Conclusions
